Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins
Status:
Completed
Trial end date:
2020-12-10
Target enrollment:
Participant gender:
Summary
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like
COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and
recruited a protein for its activation known as gp-130. Activated receptors send signals to
nucleus through secondary messenger system and up regulate the expression of IL-6/GP130
domain. Total of two hundred (n=200) participants were included in the current study and
divided equally in four groups. Group B is given Tocilizumab and Group C is treated with
Remdesivir along with the approved standard treatment. Group D is only Given standard therapy
and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130
were estimated by commercially available ELISA kit. To estimate the relationship of severity
of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity
for what purpose